Substrate

Bibliography

Biblio print

Tree Display

AceDB Schema

XML Display

Feedback

Substrate Report for: MGS0274

An ester prodrug of a metabotropic glutamate receptor 2/3 agonist with improved oral bioavailability. Its besylate is currently under development for the treatment of schizophrenia(Development code: TS-134).



General
Type: Not A/B H target, Pro-Drug, Drug
Chemical_Nomenclature: (1S,2S,3S,5R,6S)-2-Amino-3-fluoro-6-(((S)-1-(((((1R,2S,5R)-2-isopropyl-5-methylcyclohexyl)oxy)carbonyl)oxy)ethoxy)carbonyl)bicyclo[3.1.0]hexane-2-carboxylic acid
Canonical SMILES: CC1CCC(C(C1)OC(=O)OC(C)OC(=O)C2C3C2C(C(C3)F)(C(=O)O)N)C(C)C
InChI: InChI=1S/C21H32FNO7/c1-9(2)12-6-5-10(3)7-14(12)30-20(27)29-11(4)28-18(24)16-13-8-15(22)21(23,17(13)16)19(25)26/h9-17H,5-8,23H2,1-4H3,(H,25,26)/t10-,11+,12+,13+,14-,15+,16+,17+,21+/m1/s1
InChIKey: IPAZEPBIOFZFEF-UZEWAWMVSA-N
Other name(s): SCHEMBL16610461 ; HY-131336 ; CS-0133425 ; TS-134 ; MGS0274 besylatee
MW: 429.5
Formula: C21H32FNO7
CAS_number:
PubChem: 72550767
IUPHAR:
Wikipedia:

Target families
MGS0274 ligand of proteins in family: Carb_B_Chordata
No structure

Protein target
Enzyme: human-CES1

References
Search PubMed for references concerning: MGS0274
    Title: Bottom-up physiologically based pharmacokinetic modeling for predicting the human pharmacokinetic profiles of the ester prodrug MGS0274 and its active metabolite MGS0008, a metabotropic glutamate 2/3 receptor agonist
    Ochi M, Kinoshita K, Yamaguchi JI, Endo H
    Ref: Xenobiotica, :1, 2022 : PubMed

            

    Title: Discovery of MGS0274, an ester prodrug of a metabotropic glutamate receptor 2/3 agonist with improved oral bioavailability
    Urabe H, Miyakoshi N, Ohtake N, Nozoe A, Ochi M, Fukasawa M, Kinoshita K, Yamaguchi JI, Marumo T and Hashihayata T <2 more author(s)>
    Ref: Eur Journal of Medicinal Chemistry, 203:112521, 2020 : PubMed

            

    Title: Safety and pharmacokinetic profiles of MGS0274 besylate (TS-134), a novel metabotropic glutamate 2/3 receptor agonist prodrug, in healthy subjects
    Watanabe M, Marcy B, Kinoshita K, Fukasawa M, Hikichi H, Chaki S, Okuyama S, Gevorkyan H, Yoshida S
    Ref: British Journal of Clinical Pharmacology, 86:2286, 2020 : PubMed